A client develops Parkinson's clinical manifestations. Which medication does the nurse anticipate being prescribed by the health care provider (HCP) which will reduce acetylcholine levels?

A. Selegiline: This medication is a monoamine oxidase-B (MAO-B) inhibitor that works by slowing the breakdown of dopamine in the brain. It does not directly reduce acetylcholine levels but instead helps increase dopamine availability to improve motor symptoms. B. Rivastigmine: This is a cholinesterase inhibitor used in the management of dementia, particularly in Alzheimer’s and Parkinson’s disease dementia. It increases acetylcholine levels rather than decreasing them, which would worsen Parkinson’s motor symptoms. C. Benztropine: This is an anticholinergic medication that helps restore the balance between dopamine and acetylcholine in the basal ganglia. By reducing acetylcholine activity, it helps decrease tremors and muscle rigidity in clients with Parkinson’s disease. D. Levodopa carbidopa: This combination is the cornerstone of Parkinson’s therapy because it increases dopamine availability in the brain. However, it does not reduce acetylcholine levels directly, instead focusing on replenishing dopamine stores.